GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » Debt-to-Asset

Moberg Pharma AB (OSTO:MOB) Debt-to-Asset : 0.01 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB Debt-to-Asset?

Moberg Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr1.29 Mil. Moberg Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr3.14 Mil. Moberg Pharma AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr632.03 Mil. Moberg Pharma AB's debt to asset for the quarter that ended in Mar. 2024 was 0.01.


Moberg Pharma AB Debt-to-Asset Historical Data

The historical data trend for Moberg Pharma AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Debt-to-Asset Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 - 0.01 0.01 0.01

Moberg Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Competitive Comparison of Moberg Pharma AB's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Debt-to-Asset falls into.



Moberg Pharma AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Moberg Pharma AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Moberg Pharma AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.286 + 3.139) / 632.029
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moberg Pharma AB  (OSTO:MOB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Moberg Pharma AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB (OSTO:MOB) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.

Moberg Pharma AB (OSTO:MOB) Headlines